Compare MP & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MP | TECH |
|---|---|---|
| Founded | 2017 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.2B |
| IPO Year | 2020 | 1995 |
| Metric | MP | TECH |
|---|---|---|
| Price | $57.67 | $53.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $70.92 | ★ $73.09 |
| AVG Volume (30 Days) | ★ 4.6M | 2.0M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.57% |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ 0.49 |
| Revenue | $331,952,000.00 | ★ $1,219,635,000.00 |
| Revenue This Year | $114.18 | $2.49 |
| Revenue Next Year | $37.87 | $6.40 |
| P/E Ratio | ★ N/A | $114.73 |
| Revenue Growth | ★ 147.15 | 5.23 |
| 52 Week Low | $18.64 | $46.02 |
| 52 Week High | $100.25 | $72.16 |
| Indicator | MP | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 33.02 |
| Support Level | $51.73 | $48.52 |
| Resistance Level | $65.27 | $54.08 |
| Average True Range (ATR) | 3.47 | 2.26 |
| MACD | 0.14 | -0.27 |
| Stochastic Oscillator | 40.66 | 3.86 |
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.